A consolidated Mirena lawsuit litigation is continuing to move forward in New Jersey’s Bergen County Superior Court, according to recent records.
At a Case Management Conference held on November 20th, the parties discussed matters related to cases filed over the intrauterine birth control device, which hundreds of women say can spontaneously migrate away from the uterine wall and perforate the uterus. Among matters discussed were the details of a New Jersey Deposition Protocol, according to an Order issued on November 21, which involves coordination with the federal Mirena IUD lawsuit litigation. The next Case Management Conference is slated for January 14, 2014.
500+ Mirena Lawsuit Claims Now Filed in U.S.
As of November 18th, a recent Case List update showed exactly 300 lawsuits alleging Mirena complications filed in the Bergen County litigation. An update from the U.S. Judicial Panel on Multidistrict Litigation (JPML) indicated that another 267 claims had been filed in the federal Mirena lawsuit litigation underway in the U.S. District Court, Southern District of New York. These cases similarly allege spontaneous device migration, uterine perforations, ectopic pregnancy, infection and other IUD complications. The attorneys at Bernstein Liebhard LLP are actively filing claims in the federal Mirena proceeding underway in New York. (In re: Mirena IUD Products Liability Litigation, MDL No. 2434)
The Mirena IUD was approved in 2000 as a contraceptive by the U.S. Food and Drug Administration (FDA). In 2009, its list of uses expanded to the treatment of heavy menstrual bleeding in women who used it as a method of birth control. Since its launch, though, the Mirena IUD has been named in thousands of complaints filed with the U.S. Food and Drug Administration (FDA). A report published this past summer by 7 Action News pulled data from the federal agency’s database and found 70,000 adverse event reports associated with the IUD. There has been no announcement of a Mirena recall, however.
Bayer has received warning from the FDA about downplaying those side effects. In 2009, the agency sent a Warning Letter that took issue with certain promotions of Mirena, stating that benefits associated with its efficacy were overstated.